Leucovorin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Leucovorin: From Folate Rescue Therapy to Primary Hyperoxaluria
One-Sentence Summary
Leucovorin (folinic acid) is a reduced folate that bypasses the dihydrofolate reductase step. It is commonly used as a rescue agent alongside folate-antagonist chemotherapy. The TxGNN model predicts it may be effective for Primary Hyperoxaluria, but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction is graph-based only, so it should be treated as a hypothesis, not as evidence of benefit.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA record supplied (the general use is folate rescue) |
| Predicted New Indication | Primary hyperoxaluria |
| TxGNN Prediction Score | 99.41% |
| Evidence Level | L5 (model prediction only) |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, leucovorin is a reduced folate that bypasses dihydrofolate reductase. Its established role is folate rescue, not treatment of an oxalate disorder.
Primary hyperoxaluria is a metabolic disease of glyoxylate and oxalate handling. The supplied data show no direct link between folate metabolism and this pathway. The high TxGNN score (rank 3230 among all predictions) most likely reflects proximity in the knowledge graph, not a demonstrated pharmacological rationale. The mechanistic case for this indication is therefore weak and unverified.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 27/8.3/0151 | Abic leucovorin | Injection | Not stated in the record supplied |
Only an injectable form is registered. Essential Medicines List (EML) status could not be verified from the supplied data.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
No drug-interaction records were found in the data supplied. One caution from the wider prediction set is that leucovorin can mask the haematological signs of vitamin B12 deficiency while neurological damage progresses.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a graph score alone, with no trials, no literature and no established mechanistic link to oxalate metabolism. The score is not a substitute for evidence, and none of the other nine predictions in this pack has direct supporting evidence either.
To proceed, the following is needed:
- The SAHPRA Professional Information (PI) for Reg. No. 27/8.3/0151, covering approved indication, warnings and contraindications
- Mechanism of action data (from DrugBank)
- A targeted literature search on folate or folinic acid in glyoxylate/oxalate metabolism and primary hyperoxaluria
- Preclinical or mechanistic evidence before any clinical study is considered
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.